Younossi ZM, Stepanova M, Racila A, Henry L, et al. Health-Related quality of life (HRQL) assessments in a 52-Week, Double-Blind, randomized, Placebo-Controlled phase 3 study of resmetirom (MGL-3196) in patients with metabolic dysfunction associated steatohepatitis (MASH) and fibrosis. Hepatology 2024 Sep 6. doi: 10.1097/HEP.0000000000001084.
PMID: 39250515